Skip to main content
. 2021 May 11;125(2):247–254. doi: 10.1038/s41416-021-01398-7

Fig. 2. Core immunostaining of hormone-sensitive prostate cancer (HSPC) demonstrates NSD2 increases during prostate cancer progression and co-expression increases in metastases.

Fig. 2

This progression TMA consists of 44 benign, 73 primary PC specimens, of which 54 were low (GG 1–2) and 19 high grade (GG 3–5), and 22 metastases. a, b H-scores of NSD2 and EZH2 compared between benign, primary and metastatic PC radical prostatectomy cores in progression TMA (pTMA). c Percentage of individual cells staining positive for both EZH2 and NSD2 signals in benign, primary and metastatic PC (p < 0.05 indicated by *, <0.01 indicated by ** and <0.001 indicated by ***).